Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 373-382

  De Vos, Filip Y ^a   Gijtenbeek, Johanna M ^b   Bleeker Rovers, Chantal P ^b   van Herpen, Carla M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

High grade glioma; Pneumocystis jirovecii; Prophylaxis; Temozolomide

Indexed keywords

ATOVAQUONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DEXAMETHASONE; MALOPRIM; PENTAMIDINE; PREDNISOLONE; TEMOZOLOMIDE;

ANAPHYLAXIS; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN CANCER; BRAIN EDEMA; BRONCHOSPASM; CANCER GRADING; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE DENSIFICATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOBLASTOMA; HEMOLYTIC ANEMIA; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; KIDNEY DYSFUNCTION; LEUKOPENIA; LYMPHOCYTOPENIA; MENINGITIS; METHEMOGLOBINEMIA; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; PATHOGENESIS; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SKULL IRRADIATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TRANSTHORACIC BIOPSY; TREATMENT DURATION; VOMITING; WHEEZING;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; GLIOMA; HUMANS; NEOPLASM GRADING; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS;

EID: 84873526267     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.08.002     Document Type: Review

References (107)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005, 352:987-996.
2. Simpson J.R., Horton J., Scott C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. International Journal of Radiation Oncology, Biology, Physics 1993, 26:239-244.
3. Cohen M.H., Johnson J.R., Pazdur R. Food and Drug Administration approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clinical Cancer Research 2005, 11:6767-6771.
4. Mahindra A.K., Grossman S.A. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. Journal of Neuro-Oncology 2003, 63:263-270.
5. Sepkowitz K.A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases 2002, 34:1098-1107.
6. Thomas C.F., Limper A.H. Pneumocystis pneumonia. New England Journal of Medicine 2004, 350:2487-2498.
7. Choukri F., Menotti J., Sarfati, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clinical Infectious Diseases 2010, 51:259-265.
8. Ponce C.A., Gallo M., Bustamante R., Vargas S.L. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clinical Infectious Diseases 2010, 50:347-353.
9. Gianella S., Haeberli L., Joos B., et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transplant Infectious Disease 2010, 12:1-10.
10. Montes-Cano M.A., Chabe M., Fontillon-Alberdi M., et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerging Infectious Diseases 2009, 15:125-127.
11. Godeau B., Coutant-Perronne V., Le Thi Huong D., et al. Pneumocystis carinii pneumonia in the course of connective disease: report of 34 cases. Journal of Rheumatology 1994, 21:246-251.
12. Mori S., Cho I., Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. Journal of Rheumatology 2010, 37:1547-1548.
13. Lertnawapan R., Totemchokchyakarn K., Nantiruj K., Janwityanujit S. Risk factors of Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus. Rheumatology International 2009, 29:491-496.
14. Lee J.C., Bell D.C., Guinness R.M., Ahmad T. Pneumocystis jirovecii pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis. World Journal of Gastroenterology 2009, 15:1897-1900.
15. Velayos F.S., Sandborn W.J. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Chrohn's disease. Inflammatory Bowel Disease 2004, 10:657-660.
16. Worth L.J., Dooley M.J., Seymour J.F., Mileshkin L., Slavin M.A., Thursky K.A. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer 2005, 92:867-872.
17. Torres H.A., Chemaly R.F., Storey R., et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jirovecii pneumonia in cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 2006, 25:382-388.
18. Barbounis V., Aperis G., Gambletsas E., et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Research 2005, 25:651-655.
19. Dall'oglio S., D'Amico A., Pioli F., et al. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. Journal of Neuro-Oncology 2008, 90:315-319.
20. Hughes W.T., Feldman S., Aur R.J., Verzosa M.S., Hustu H.O., Simone J.V. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975, 36:2004-2009.
21. Enomoto T., Azuma A., Kohno A., et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respiratology 2010, 15:126-131.
22. Mansharamani N.G., Garland R., Delaney D., Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000, 118:704-711.
23. Festic E., Gaijc O., Limper A.H., Aksamit T.R. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005, 128:573-579.
24. Vogel M.N., Vatlach M., Weissgerber P., et al. HRCT-features of Pneumocystis jirovecii pneumonia and their evolution before and after treatment of non-HIV immunocompromised patients. European Journal of Radiology 2011, [Epub ahead of print].
25. Reid A.B., Chen S.C., Worth L.J. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Current Opinion in Infectious Diseases 2011, 24:534-544.
26. Robberts F.J., Liebowitz L.D., Chalkley L.J. Polymerase chain reaction detection of Pneumocystis jirovecii: evaluation of 9 assays. Diagnostic Microbiology and Infectious Disease 2007, 58:385-392.
27. Fujisawa T., Suda T., Matsuda H., et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 2009, 14:203-209.
28. Nakazato T., Mihara A., Sanada Y., et al. Pneumocystis jirovecii pneumonia detected by FDG-PET. Annals of Hematology 2010, 89:839-840.
29. Shimizu Y., Sunaga N., Dobashi K., et al. Serum markers in interstitial pneumonia with or without Pneumocystis jirovecii colonization: a prospective study. BMC Infectious Diseases 2009, 9:47-52.
30. Chen W., Havell E.A., Harmsen A.G. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infection and Immunity 1992, 60:1279-1284.
31. Iriart X., Witkowski B., Courtes C., et al. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection. Medical Mycology 2010, 48:1075-1087.
32. Gold E. Infections associated with immunologic deficiency diseases. Medical Clinics of North America 1974, 58:649-659.
33. Hanano R., Reifenberg K., Kaufmann S.H. Activated pulmonary macrophages are insufficient for resistance against Pneumocystis carinii. Infection and Immunity 1998, 66:305-314.
34. Mansharamani N.G., Balachandran D., Vernovsky I., Garland R., Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000, 118:712-720.
35. Masur H., Lane H.C., Kovacs J.A., Allegra C.J., Edman J.C., Conference N.I.H. Pneumocystis pneumonia: from bench to clinic. Annals of Internal Medicine 1989, 111:813-826.
36. Cheung C., Shuter J. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy. International Journal of STD and AIDS 2010, 21:406-409.
37. National Cancer Institute. SEER Cancer Statistics Review, 1975-2008, Available at ; 2011 [accessed 18.09.11]. http://seer.cancer.gov/statfacts/html/brain.html.
38. Goldmann J., Kwidzinski E., Brandt C., Mahlo J., Richter D., Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and nasal mucosa. Journal of Leukocyte Biology 2006, 80:797-801.
39. Calzascia T., Masson F., Di Berardino-Besson W., et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005, 22:175-184.
40. Heimberger A.B., Sampson J.H. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Journal of Neuro-Oncology 2011, 13:3-13.
41. El Andaloussi A., Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Journal of Neuro-Oncology 2006, 8:234-243.
42. Brantley E.C., Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Molecular Cancer Research 2008, 6:675-684.
43. Jacobs J.F.M., Idema A.J., Bol K.F., et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Journal of Neuro-Oncology 2009, 11:394-402.
44. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
45. Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Annals of Internal Medicine 1993, 119:1198-1208.
46. Emeson E.E., Norin A.J., Veith F.J. Antigen-induced recruitment of circulating lymphocytes to the lungs and hilar lymph nodes of mice challenged intratracheally with alloantigens. American Review of Respiratory Disease 1982, 125:453-459.
47. Walzer P.D., Powell R.D., Yoneda K., Rutledge M.E., Milder J.E. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infection and Immunity 1980, 27:928-937.
48. Walzer P.D., LaBine M., Redington T.J., Cushion M.T. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. Journal of Immunology 1984, 133:2502-2508.
49. Henson J.W., Jalaj J.K., Walker R.W., Stover D.E., Fels A.O. Pneumocystis carinii pneumonia in patients with primary brain tumors. Archives of Neurology 1991, 48:406-409.
50. Slivka A., Wen P.Y., Shea W.M., Loeffler J.S. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. American Journal of Medicine 1993, 94:216-219.
51. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. Journal of Neuro-Oncology 1996, 27:235-240.
52. Pruitt A.A. Treatment of medical complications in patients with brain tumors. Current Treatment Options in Neurology 2005, 7:323-336.
53. Kleinberg L., Grossman S.A., Piantadosi S., Zeltzman W., Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. International Journal of Radiation Oncology, Biology, Physics 1999, 44:535-543.
54. Hughes M.A., Parisi M., Grossman S., Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 count and risk of infection. International Journal of Radiation Oncology, Biology, Physics 2005, 62:1423-1426.
55. Kizilarslanoglu M.C., Aksoy S., Yildirim N.O., Ararat E., Sahin I., Altundag K. Temozolomide-related infections: review of the literature. J BUON 2011, 16:547-550.
56. Marosi C. Complications of chemotherapy in neuro-oncology. Journal of Balkan Union of Oncology 2012, 105:873-885.
57. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Journal of Clinical Oncology 2002, 20:1375-1382.
58. Green H., Paul M., Vidal L., Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocomprimised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clinic Proceedings 2007, 82:1052-1059.
59. Grossman S.A., Ye X., Lesser G.J., Sloan A., Carson C., Piantadosi S. Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: a NABTT CNS consortium study [abstract]. Journal of Clinical Oncology 2010, 28(suppl.):2013.
60. Grossman S.A., Ye X., Lesser G., et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research 2011, 17:5473-5480.
61. Neyns B., Tosoni A., Hwu W.J., Reardon D.A. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010, 116:2868-2877.
62. Fadul C.E., Fisher J.L., Gui J., Hampton T.H., Côté A.L., Ernstoff M.S. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Journal of Neuro-Oncology 2011, 13:393-400.
63. Wick A., Felsberg J., Steinbach J.P., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Journal of Clinical Oncology 2007, 25:3357-3361.
64. Berrocal A., Perez Segura P., Gil M., et al. Extended-schedule dose-dense temozolomide in refractory gliomas. Journal of Neuro-Oncology 2010, 96:417-422.
65. Abacioglu U., Caglar H.B., Yumuk P.F., Akgun Z., Atasoy B.M., Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 2011, 103:585-593.
66. Neyns B., Chaskis C., Joosens E., et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Investigation 2008, 26:269-277.
67. Tosoni A., Cavallo G., Ermani M., et al. Is protracted low-dose temozolomide feasible in glioma patients?. Neurology 2006, 66:427-429.
68. Ganière V., Christen G., Bally F., et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nature Clinical Practice Oncology 2006, 3:339-343.
69. Stupp R., Tonn J.C., Brada M., Pentheroudakis G. High-grade malignant glioma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology 2010, 21:v190-v193.
70. Cancer Council Australia. Adult gliomas (astrocytomas and oligodendrogliomas): a guide for patients, their families and carers, Available at ; 2011 [accessed 18.05.12]. http://www.cancer.org.au/File/HealthProfessionals/Clinical%20Guidelines/Adult_Glioma_Consumer_Guide_FINAL_bookmarked.pdf.
71. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Central Nervous System Cancers. Version 1.2012 Available at [accessed 18.05.12]. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
72. Siker M.L., Chakravarti A., Mehta M.P. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy with anaplastic glioma?. Critical Reviews in Oncology/Hematology 2006, 60:99-111.
73. Stansell J.D., Osmond D.H., Charlebois E., et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary complications of HIV infection study group. American Journal of Respiratory and Critical Care Medicine 1997, 155:60-66.
74. Segal B.H., Freifeld A.G., Baden L.R., et al. Prevention and treatment of cancer-related infections. Journal of the National Comprehensive Cancer Network 2008, 6:122-174.
75. Rodriguez M., Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clinical Microbiology Reviews 2004, 17:770-782.
76. Ioannidis J.P., Cappelleri J.C., Skolnik P.R., Lau J., Sacks H.S. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Archives of Internal Medicine 1996, 156:177-188.
77. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Morbidity and Mortality Weekly Report Recommendations and Reports 2009, 58:1-207.
78. Meyers M.W., Jick H. Hospitalization for serious blood and skin disorders following co-tromixazol. British Journal of Clinical Pharmacology 1997, 43:649-651.
79. Douzinas E.E., Flevari K., Andrianakis I., Betrosian A.P. Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency. Scandinavian Journal of Infectious Diseases 2010, 42:76-78.
80. Bucher H.C., Griffith L., Guyatt G.H., Opravil M. Meta-analysis of prophylactic treatments against Pneumocytis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997, 15:104-114.
81. Lin D., Li W.K., Rieder M.J. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database of Systematic Reviews 2007, 2:CD005646.
82. Rizzardi G.P., Lazzarin A., Musicco M., et al. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentre randomized controlled trial. Journal of Infection 1996, 32:123-131.
83. May T., Beuscart C., Reynes J., et al. Trimethorpim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. Journal of Acquired Immune Deficiency Syndromes 1994, 7:457-462.
84. Schneider M.M., Hoepelman A.I., Eeftinck Schattenkerk J.K., et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodificiency virus infection. New England Journal of Medicine 1992, 327:1836-1841.
85. Podzamczer D., Salazar A., Jiménez J., et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Annals of Internal Medicine 1995, 122:755-761.
86. Podzamczer D., Santín M., Jimenez J., Casanova A., Bolao F., Gudiol G.R. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993, 7:501-506.
87. Blum R.N., Miller L.A., Gaggini L.C., Cohn D.L. Comparative trial dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. Journal of Acquired Immune Deficiency Syndromes 1992, 5:341-347.
88. Bozzette S.A., Finkelstein D.M., Spector S.A., et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1995, 332:693-699.
89. Slavin M.A., Hoy J.F., Stewart K., Pettinger M.B., Lucas C.R., Kent S.J. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992, 6:1169-1174.
90. Girard P.M., Landman R., Gaudebout C., et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. New England Journal of Medicine 1993, 328:1514-1520.
91. Torres R.A., Barr M., Thorn M., et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. American Journal of Medicine 1993, 95:573-583.
92. Opravil M., Hirschel B., Lazzarin A., et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 1995, 20:531-541.
93. Baggish A.L., Hill D.R. Antiparasitic agent atovaquone. Antimicrobial Agents and Chemotherapy 2002, 46:1163-1173.
94. Chan C., Montaner J., Lefebvre E.A., et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. Journal of Infectious Diseases 1999, 180:369-376.
95. El-Sadr W.M., Murphy R.L., Yurik T.M., Luskin-Hawk R., Cheung T.W., Balfour H.H. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. New England Journal of Medicine 1998, 339:1889-1895.
96. Colby C., McAfee S., Sackstein R., et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1999, 24:897-902.
97. Antinori A., Murri R., Ammassari A., et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995, 9:1343-1350.
98. Mallolas J., Zamora L., Gatell J.M., et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993, 7:59-64.
99. Toccheti A., Tambini R., Allegro A., Longoni E., Rinaldi E. Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. AIDS 1994, 8:272-274.
100. Jick H., Derby L.E. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995, 15:428-432.
101. Myers M.W., Jick H. Hospitalization for serious blood and skin disorders following co-trimoxazole. British Journal of Clinical Pharmacology 1997, 43:649-651.
102. Masters P.A., OóBryan T.A., Zurlo J., Miller D.Q., Joshi N. Trimethoprim-sulfamethoxazole revisited. Archives of Internal Medicine 2003, 163:402-410.
103. Sibanda E.L., Weller I.V., Hakim J.G., Cowan F.M. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clinical Infectious Diseases 2011, 52:1184-1194.
104. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
105. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 24:3187-3205.
106. Brandes A.A., Compostella A., Blatt V., Tosoni A. Glioblastoma in the elderly: current and future trends. Critical Reviews in Oncology/Hematology 2006, 60:256-266.
107. Yovino S., Grossman S.A. Treatment of glioblastoma in " elderly" patients. Current Treatment Options in Oncology 2011, 12:253-262.